Is dasatinib a targeted drug?

Dasatinib (Dasatinib) Dasatinib is a targeted drug used to treat certain types of cancer, specifically chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It is a small molecule tyrosine kinase inhibitor that specifically targets and inhibits the activity of the BCR-ABL fusion protein, which is produced by the Philadelphia chromosomal abnormality in most cases of CML. By blocking this signaling pathway, dasatinib can effectively interfere with the proliferation and survival of cancer cells, thereby inhibiting tumor development.

The targeted therapeutic mechanism of dasatinib enables it to demonstrate significant efficacy and safety in clinical application. Compared with traditional chemotherapy drugs, targeted drugs usually have higher selectivity, can reduce damage to normal cells and reduce the incidence of side effects. For example, the use of dasatinib can significantly increase the complete remission rate in patients and has also shown good responses in patients who had previously failed other treatments.

In addition, in addition to targetingBCR-ABL, dasatinib also has inhibitory effects on several other tyrosine kinases, such as SRC family kinases. This property not only enhances its anti-tumor effect, but also provides a broader therapeutic potential. Studies have shown that dasatinib can still achieve promising results when treating some patients who are resistant to first-line treatment.

In clinical practice, the use of dasatinib requires doctors to formulate a treatment plan based on the patient's specific conditions, including dosage, administration, and monitoring. At the same time, patients need to undergo regular blood tests while using dasatinib to monitor the effect of the drug and potential adverse reactions, such as thrombocytopenia, abnormal liver function, etc.

In short, dasatinib, as a targeted drug, has shown strong clinical value in the treatment of chronic myelogenous leukemia and acute lymphoblastic leukemia. Its unique mechanism of action and relatively few side effects make it an important part of modern tumor treatment and promote the development of targeted therapy.

Reference materials:https://go.drugbank.com/drugs/DB01254